almagate has been researched along with oligonucleotides in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (84.21) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamis, AP; Cunningham, ET; Feinsod, M; Gragoudas, ES; Guyer, DR | 1 |
| Nimjee, SM; Rusconi, CP; Sullenger, BA | 1 |
| Fine, SL; Kirkpatrick, P; Martin, DF | 1 |
| Coster, DJ; van Wijngaarden, P; Williams, KA | 1 |
| Schachat, AP | 1 |
| Morrow, T | 1 |
| Blaise, P; Foidart, JM; Rakic, JM | 1 |
| Keating, GM; Siddiqui, MA | 1 |
| Hansen, MH; Mortensen, KK; Sjølie, AK | 1 |
| Haamann, PH; la Cour, M; Larsen, M; Lund-Andersen, H; Sander, B; Villumsen, JE | 1 |
| Adamis, AP; Aiello, LP; Altaweel, M; Bressler, NM; Cunningham, ET; D'Amico, DJ; Goldbaum, M; Guyer, DR; Katz, B; Patel, M; Schwartz, SD | 1 |
| Bozza, M; Dilone, E; Galazka, M; Scypinski, S; Sheardy, RD | 1 |
| Wacheck, V | 1 |
| Winkler, J | 1 |
| Goto, R; Inomata, E; Miyakawa, S; Nakamura, Y; Takami, T; Yamaura, J | 1 |
| Castanotto, D; Stein, CA | 1 |
6 review(s) available for almagate and oligonucleotides
| Article | Year |
|---|---|
Aptamers: an emerging class of therapeutics.
Topics: Animals; Anti-Infective Agents; Antidotes; Aptamers, Nucleotide; Bacterial Proteins; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Drugs, Investigational; Gene Library; HIV Infections; Humans; Oligonucleotides; Transcription Factors; Viral Proteins | 2005 |
Inhibitors of ocular neovascularization: promises and potential problems.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Injections; Macular Degeneration; Oligonucleotides; Ranibizumab; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib: in exudative age-related macular degeneration.
Topics: Animals; Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Randomized Controlled Trials as Topic; Visual Acuity; Vitreous Body | 2005 |
[Oligonucleotide therapeutics - an emerging novel class of compounds].
Topics: Aptamers, Nucleotide; Drug Delivery Systems; Gene Expression; Humans; Oligodeoxyribonucleotides; Oligonucleotides; Oligonucleotides, Antisense; RNA, Small Interfering; Structure-Activity Relationship; Thionucleotides | 2006 |
Therapeutic oligonucleotides with polyethylene glycol modifications.
Topics: Animals; Aptamers, Nucleotide; Drug Discovery; Humans; Oligonucleotides; Oligonucleotides, Antisense; Polyethylene Glycols; RNA, Small Interfering | 2015 |
FDA-Approved Oligonucleotide Therapies in 2017.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Cytomegalovirus Retinitis; Drug Approval; Hepatic Veno-Occlusive Disease; Humans; Hypercholesterolemia; Macular Degeneration; Morpholinos; Muscular Atrophy, Spinal; Muscular Dystrophy, Duchenne; Oligonucleotides; Oligonucleotides, Antisense; Polydeoxyribonucleotides; Thionucleotides | 2017 |
3 trial(s) available for almagate and oligonucleotides
| Article | Year |
|---|---|
Pegaptanib for neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Prospective Studies; Radiography; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2004 |
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Treatment Outcome; Vascular Endothelial Growth Factors; Visual Acuity; Vitreous Body | 2005 |
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Topics: Adult; Aged; Aged, 80 and over; Aptamers, Nucleotide; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Injections; Macular Edema; Male; Middle Aged; Oligonucleotides; Safety; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2005 |
10 other study(ies) available for almagate and oligonucleotides
| Article | Year |
|---|---|
New drugs and dosage forms.
Topics: Adenine Nucleotides; Adolescent; Adult; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Child; Child, Preschool; Clofarabine; Contraindications; Diethylcarbamazine; Dosage Forms; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Humans; Iloprost; Infant; Meglumine; Middle Aged; Oligonucleotides; omega-Conotoxins; Organometallic Compounds; Piperazines; Saquinavir; Trypan Blue | 2005 |
Pegaptanib sodium.
Topics: Aptamers, Nucleotide; Double-Blind Method; Humans; Macular Degeneration; Oligonucleotides; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
New treatments for age-related macular degeneration.
Topics: Aptamers, Nucleotide; Dietary Supplements; Humans; Laser Coagulation; Macular Degeneration; Oligonucleotides; Ophthalmologic Surgical Procedures; Photochemotherapy; Pregnadienediols | 2005 |
Aptamers: slowing progression of AMD.
Topics: Age Factors; Aptamers, Nucleotide; Disease Progression; Humans; Macular Degeneration; Oligonucleotides; United States; Vision, Ocular | 2005 |
Pegaptanib and age-related macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Dose-Response Relationship, Drug; Humans; Injections; Macular Degeneration; Oligonucleotides; Vitreous Body | 2005 |
New drug treats form of age-related macular degeneration. Macugen inhibits progression of wet AMD and also may restore some vision.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Humans; Macular Degeneration; Oligonucleotides | 2005 |
Pegaptanib sodium (Macugen) for macular degeneration.
Topics: Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Vision Disorders; Vitreous Body | 2005 |
[Antiangiogenesis therapy of age-related macular degeneration].
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Vascular Endothelial Growth Factors; Vitreous Body | 2005 |
Characterization of the secondary structure and stability of an RNA aptamer that binds vascular endothelial growth factor.
Topics: Aptamers, Nucleotide; Base Sequence; Calorimetry, Differential Scanning; Circular Dichroism; Dose-Response Relationship, Drug; Humans; Nucleic Acid Conformation; Nucleic Acid Denaturation; Oligonucleotides; Polyethylene Glycols; Protein Binding; RNA; Sodium Chloride; Temperature; Thermodynamics; Vascular Endothelial Growth Factor A | 2006 |
De novo sequencing of highly modified therapeutic oligonucleotides by hydrophobic tag sequencing coupled with LC-MS.
Topics: Aptamers, Nucleotide; Base Sequence; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Hydrophobic and Hydrophilic Interactions; Molecular Weight; Oligonucleotides; Spectrometry, Mass, Electrospray Ionization; Vascular Endothelial Growth Factor A | 2017 |